open access

Vol 11, No 5 (2016)
Review Papers
Published online: 2016-09-14
Get Citation

The role of circulating receptor for IL-33 (sST2) in monitoring treatment of heart failure

Joanna Jędrzejczyk-Spaho, Paweł Rostoff, Jadwiga Nessler
DOI: 10.5603/FC.a2016.0074
·
Folia Cardiologica 2016;11(5):415-420.

open access

Vol 11, No 5 (2016)
Review Papers
Published online: 2016-09-14

Abstract

Heart failure (HF) is currently one of the major health problems in Poland and in other European countries. Despite the progress that has been made in the treatment of HF, mortality and the incidence of re-hospitalization for HF are still very high. One of the reasons is the lack of proper heart failure treatment optimization.
Among the currently studied new biomarkers of heart failure, one of the special interest is circulating receptor for IL-33 (sST2). It has been shown that IL-33 plays cardioprotective role. Its molecular mechanisms of action are based mainly on the activation of the transmembrane form of ST2 receptor (ST2L). Availability of IL-33 for ST2L is limited by binding to the soluble fraction of the ST2 (sST2) — called a „decoy receptor”.
The presence of elevated levels of sST2 in the population of patients with heart failure is associated with more severe left ventricular remodeling, impaired diastolic function and right ventricle function. Patients with both HF and high and/or rising levels sST2 are at high risk of adverse cardiovascular events.
The standard treatment for heart failure leads to reduction in sST2 concentration. Among the drugs used in the heart failure treatment, two with the largest impact on reducing concentration of sST2 are beta-blockers in high doses, and aldosterone.

Abstract

Heart failure (HF) is currently one of the major health problems in Poland and in other European countries. Despite the progress that has been made in the treatment of HF, mortality and the incidence of re-hospitalization for HF are still very high. One of the reasons is the lack of proper heart failure treatment optimization.
Among the currently studied new biomarkers of heart failure, one of the special interest is circulating receptor for IL-33 (sST2). It has been shown that IL-33 plays cardioprotective role. Its molecular mechanisms of action are based mainly on the activation of the transmembrane form of ST2 receptor (ST2L). Availability of IL-33 for ST2L is limited by binding to the soluble fraction of the ST2 (sST2) — called a „decoy receptor”.
The presence of elevated levels of sST2 in the population of patients with heart failure is associated with more severe left ventricular remodeling, impaired diastolic function and right ventricle function. Patients with both HF and high and/or rising levels sST2 are at high risk of adverse cardiovascular events.
The standard treatment for heart failure leads to reduction in sST2 concentration. Among the drugs used in the heart failure treatment, two with the largest impact on reducing concentration of sST2 are beta-blockers in high doses, and aldosterone.

Get Citation

Keywords

sST2, heart failure, biochemical markers, monitoring of therapy

About this article
Title

The role of circulating receptor for IL-33 (sST2) in monitoring treatment of heart failure

Journal

Folia Cardiologica

Issue

Vol 11, No 5 (2016)

Pages

415-420

Published online

2016-09-14

DOI

10.5603/FC.a2016.0074

Bibliographic record

Folia Cardiologica 2016;11(5):415-420.

Keywords

sST2
heart failure
biochemical markers
monitoring of therapy

Authors

Joanna Jędrzejczyk-Spaho
Paweł Rostoff
Jadwiga Nessler

References (23)
  1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic ure 2012 of the European Society of Cardiology. Developed in collaboration with the ure Association (HFA) of the ESC. Eur. J. Heart Fail. 2012; 14: 803–869.
  2. Straburzyńska-Migaj E, Nessler J. Ostra niewydolność serca w zarysie. Via Medica, Gdańsk 2015.
  3. de Boer RA, Daniels LB, Maisel AS, et al. State of the Art: Newer biomarkers in heart failure. Eur J Heart Fail. 2015; 17(6): 559–569.
  4. Januzzi JL, Pascual-Figal D, Daniels LB. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol. 2015; 115(7 Suppl): 70B–75B.
  5. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015; 115(7 Suppl): 3B–7B.
  6. Weir RAP, Miller AM, Murphy GEJ, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010; 55(3): 243–250.
  7. Harris EK, Yasaka T. On the calculation of a "reference change" for comparing two consecutive measurements. Clin Chem. 1983; 29(1): 25–30.
  8. Wu AHB, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J. 2013; 165(6): 995–999.
  9. Wu AHB, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003; 92(5): 628–631.
  10. Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2013; 62(16): e147–e239.
  11. Januzzi J, Peacock W, Maisel A, et al. Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea. Journal of the American College of Cardiology. 2007; 50(7): 607–613.
  12. Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008; 14(9): 732–738.
  13. Manzano-Fernández S, Januzzi JL, Pastor-Pérez FJ, et al. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology. 2012; 122(3): 158–166.
  14. Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail. 2013; 19(12): 821–828.
  15. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012; 126(13): 1596–1604.
  16. Zilinski JL, Shah RV, Gaggin HK, et al. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care. 2012; 16(4): R135.
  17. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, et al. MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009; 54(23): 2174–2179.
  18. Januzzi JL, Horne BD, Moore SA, et al. Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers. 2013; 18(3): 250–256.
  19. Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail. 2013; 6(6): 1206–1213.
  20. Anand IS, Rector TS, Kuskowski M, et al. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014; 7(3): 418–426.
  21. Maisel A, Xue Y, van Veldhuisen DJ, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol. 2014; 114(5): 737–742.
  22. Broch K, Ueland T, Nymo SH, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail. 2012; 14(3): 268–277.
  23. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014; 2(1): 65–72.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl